Expansion WNBA team brings back original Portland Fire name
The expansion franchise, which begins play next season along with the Toronto Tempo, announced its name and branding on Tuesday, reviving the moniker of the city's previous WNBA team that played from 2000 to 2002.
"Our feeling is that the fire never died," interim Fire president Clare Hamill said. "Fans have been waiting for us to come back, and we're back with the Portland Fire."
In addition to the name, the team has a new "Rose on Fire" logo and a colour palette of red, brown, blue and pink.
Portland Trail Blazers owner Paul Allen, the co-founder of Microsoft who died in 2018, was chairman of the original Fire and the two teams played at the Rose Garden, now the Moda Center.
The NBA owned the WNBA teams until 2002, then sold them to affiliated NBA teams or independent owners. Allen declined to buy the Fire and the team folded.
Portland was awarded a new WNBA team last September. The team is run by Raj Sports, led by Lisa Bhathal Merage and Alex Bhathal, who also own the Portland Thorns of the National Women's Soccer League. They paid $125 million US for the WNBA franchise.
The Fire and Thorns will share a new joint-training facility in the first such partnership between the two women's leagues.
The Fire already have sold more than 11,000 season tickets, surpassing the WNBA's previous best. The team will play at the Moda Center, where the original Fire averaged some 8,000 fans a game.
Team president left team in June
But the launch of the team hasn't been smooth.
Indications the team planned to return to the Fire name were previously revealed when a local publication, the Rose Garden Report, published the team's trademark application.
The team's president, Inky Son, parted ways with the team late last month after less than three months on the job. Son was announced as the first employee of the team in early April, tasked with leading all aspects of the business, including marketing, ticket and sponsorship sales, and community relations.
The Tempo, meanwhile, announced a team name back in December and already have a general manager.
Hamill, a former Nike executive, took over for Son until a permanent president can be found. She said the launch of the team name and logo is just a slice of what the team is activating on Tuesday.
"We're pointing everybody to the launch and the pace at which we're moving, and just giving everyone confidence that we have our arms around it," Hamill said. "We're moving fast, and you're going to hear from us a lot."
The team planned to celebrate the name and logo launch with a community party on Tuesday afternoon at the Moda Center.
Meet Monica Wright Rogers, the GM of the WNBA's newest team, the Toronto Tempo
5 months ago
The newly hired Tempo general manager talks goals for the 2026 WNBA season and how she plans to build a championship-winning team.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
35 minutes ago
- Globe and Mail
Here's Why This $50 Healthcare Stock Could Be the Next $200 Winner
Key Points Exelixis' most important product should continue driving strong financial results through the end of the decade. The oncology specialist is working on a next-gen medicine that could be even better than its crown jewel. The midcap biotech looks well-positioned to deliver market-beating returns over the long run. 10 stocks we like better than Exelixis › A decade ago, shares of Exelixis (NASDAQ: EXEL), a biotech company specializing in oncology, were trading for under $10 per share. Today, the drugmaker's shares are changing hands for about $45 apiece. In other words, Exelixis has crushed the market since 2015. Some might think there is little upside left for the stock after this run, but that's not the case. Read on to find out why Exelixis still has plenty of growth fuel left in the tank. EXEL Total Return Level data by YCharts. Cabometyx is still doing the heavy lifting Exelixis is best known for its cancer medicine, Cabometyx. First approved in the U.S. in 2016 for patients with renal cell carcinoma (RCC, a form of kidney cancer), it was a bit of a breakthrough as the first therapy to show significant improvements for RCC patients in three important measures: overall survival, progression-free survival, and objective response rate (the percentage of patients who respond to treatment). Cabometyx has since earned numerous label expansions, and it continues to help drive solid top- and bottom-line growth for Exelixis. In the first quarter, the company's revenue jumped by 30.6% year over year to $555.4 million. The company's adjusted earnings per share (EPS) more than tripled to $0.62. Cabometyx has proven to be a successful pipeline drug, becoming the most prescribed tyrosine kinase inhibitor (a type of cancer drug that targets and kills cancer cells) among RCC patients, while making headway in hepatocellular carcinoma (liver cancer) and other markets. Despite Cabometyx's success, though, Exelixis will need more to continue delivering above-average returns over the long run. Generic competition for the medicine is expected to enter the U.S. market by 2030. Thankfully, Exelixis is already preparing for that eventuality. The next stage of growth Exelixis aims to apply the same blueprint that has made it successful over the past decade: developing a cancer medicine that can become a standard of care in a niche with a high unmet need, while earning label expansions in many other markets. The company appears to have already discovered its next gem. Exelixis recently reported positive top-line phase 3 results for zanzalintinib in patients with metastatic colorectal cancer (CRC). Despite having a high 5-year survival rate when caught early, CRC is the second-leading cause of cancer death worldwide partly because, once it has metastasized, there are few effective treatment options. Exelixis is looking to change that with zanzalintinib, and the company's apparent phase 3 success suggests it might be able to pull it off. Furthermore, zanzalintinib is being investigated across other indications, including those where Cabometyx is dominant, such as RCC. The former seems to have a better safety profile than its predecessor, among several other advantages. Beyond RCC and CRC, Exelixis plans to start several other late-stage studies for its next crown jewel this year, all of which will test it against current standards of care. As they say, to be the best, you have to beat the best. That's what Exelixis aims to do with zanzalintinib. Exelixis expects zanzalintinib to generate about $5 billion in sales eventually, far exceeding Cabometyx's current total or, for that matter, Exelixis' annual revenue. There is still some work to be done to get there, but early signs suggest that zanzalintinib is an excellent candidate. Exelixis' recent clinical progress also reinforces its leadership in oncology. The biotech company has several other early-stage candidates in development that could help it move beyond Cabometyx once it starts facing generic competition. Can Exelixis get to $200? From its current stock price of approximately $45, Exelixis needs a compound annual growth rate (CAGR) of at least 16.1% to reach $200 within the next decade and 10.5% to achieve this in 15 years. The former goal is ambitious, but the stock has delivered even better returns than that over the past decade. Although the past is no guarantee of future success, Exelixis' MO has remained the same and could, once again, allow it to generate monster returns over the long run as it makes significant clinical and regulatory progress with zanzalintinib and other pipeline candidates. Even if it falls short of this goal, though, my view is that Exelixis is well-positioned to deliver market-beating returns to patient investors -- the 15-year path to $200 would still be impressive. Either way, the stock looks like a buy. Should you invest $1,000 in Exelixis right now? Before you buy stock in Exelixis, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Exelixis wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
an hour ago
- Globe and Mail
Is Nvidia Stock Too Expensive to Buy Now?
Key Points Data center growth is slated to continue for some time. Nvidia's GPUs are unrivaled in the AI space. Many stocks trade at the same price tag as Nvidia with far less growth. 10 stocks we like better than Nvidia › Nvidia (NASDAQ: NVDA) has been the top artificial intelligence (AI) stock to own for some time now, but with its latest rise, many investors are concerned that Nvidia's stock is too expensive to buy more shares at the current price. While I understand the hesitation, I think there is a compelling argument that Nvidia isn't expensive when you take a longer view than just a single year. If you can commit to owning Nvidia stock for three to five years, I think there's a good reason to buy the stock right now. However, if you're only looking at a single year, the stock may appear somewhat pricey. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Data center expansion will continue to be a massive source of growth Nvidia is the global leader in graphics processing units (GPUs), and it has established this position through superior hardware and unmatched software that allow users to optimize GPUs for various workloads. One estimate pegs Nvidia's data center market share for GPUs at 90%, which underscores just how widely used Nvidia's products are. GPUs aren't just popular for AI workloads; they're used whenever an arduous computing task is involved. Whether it's drug discovery, cryptocurrency mining, engineering simulations, or their original purpose, gaming graphics, GPUs excel at the task because of their ability to process multiple calculations in parallel. Combine that with the ability to connect GPUs in clusters, and their computing power can be quickly amplified. As more data centers are built, the demand for GPUs is expected to rise, which will likely benefit Nvidia's stock over the long term. For 2025, the AI hyperscalers all announced record capital expenditures, with most of the funds going toward data center construction. While this is impressive, the records are likely to be shattered again in 2026, as data center construction spans multiple years. This supports a third-party projection that Nvidia cited during its 2025 GTC conference, stating that 2024 global data center capital expenditures totaled $400 billion but are expected to rise to $1 trillion by 2028. Should that occur, Nvidia's stock has plenty of room to run, as it captures a large portion of that spending. In the company's fiscal-year 2025 (which encompasses most of 2024), its data center revenue totaled $115 billion, which means Nvidia captures nearly 30% of total data center spending. If it can maintain that market share, it has the potential to generate $300 billion from data centers alone, provided the projection comes true. That's a significant upside from today's totals, making today's stock price appear less expensive than it initially seems. Nvidia's stock appears expensive, but so do many others in the market Currently, Nvidia's stock trades at about 40 times forward earnings. NVDA PE Ratio (Forward) data by YCharts That's historically quite expensive, but few companies have been able to sustainably grow as quickly as Nvidia. For Q2, Nvidia expects 50% revenue growth, which is far more than the majority of companies in the market. Furthermore, if you're going to call Nvidia expensive, then there are countless other stocks investors must be cautious with. Stocks like Amazon (NASDAQ: AMZN) (36 times forward earnings), Eli Lilly (NYSE: LLY) (35 times forward earnings), and Costco Wholesale (NASDAQ: COST) (53 times forward earnings) are just as expensive as Nvidia, yet don't have near the growth rate or upside. NVDA PE Ratio (Forward) data by YCharts I think it's safe to say that the broader market is rather expensive as a whole, but with how rapidly Nvidia is growing and how bright its long-term prospects are, I think investors are still safe to pick up shares here, as long as they have the mindset that they're holding for three to five years. If you can keep that time frame in mind, Nvidia is still a compelling investment. Should you invest $1,000 in Nvidia right now? Before you buy stock in Nvidia, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Nvidia wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
Globe and Mail
an hour ago
- Globe and Mail
Should You Invest $1,000 in Quantum Computing Competitor Rigetti Computing?
Key Points Rigetti Computing is a pure-play quantum computing investment. Investors must understand the risks associated with investing in Rigetti. A massive quantum computing market is expected to emerge by 2030. 10 stocks we like better than Rigetti Computing › Quantum computing is an intriguing investment field. Right now, there's a ton of money pouring into the technology, but it really isn't adding any value back into the economy. That's because it's still a fledgling technology that's working its way toward commercial viability. However, once it reaches that point, the companies involved in this space could see their stocks skyrocket alongside demand. Rigetti Computing (NASDAQ: RGTI) is a company in the quantum computing race, and it's a popular pick among investors. However, is now the right time to invest $1,000 into the stock? Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More » Image source: Getty Images. Rigetti Computing is a high-risk, high-reward investment Rigetti Computing is a pure play within the quantum computing investment realm, which means it's quantum computing relevancy or bust. This has several benefits and drawbacks. On the positive side, the company is laser-focused on quantum computing and is devoting every bit of its resources to investing in the technology and bringing it to market. Additionally, if Rigetti Computing succeeds in its goal to achieve quantum computing relevancy, its stock is primed to soar because it has no revenue to speak of right now (besides some that it gets from research contracts). Rigetti Computing is only a $4 billion business, so it has immense upside if it can achieve significant growth. The downside of investing in quantum computing pure plays is that there is no backup plan. If another competitor and its technology surpass Rigetti's, the stock becomes obsolete, and every share is worthless, ultimately sending the stock to $0. That's a grim outlook, but it's entirely within the realm of possibility. Furthermore, because its only cash sources are various contracts, issuing new shares, or taking on debt, it doesn't have the financial backing that some of the large tech companies competing in quantum computing have. For example, one large competitor in this space is Alphabet, the parent company of Google. Over the past 12 months, Alphabet produced a jaw-dropping $75 billion in free cash flow. It means nothing for Alphabet to sink $1 billion into the quantum computing race -- a sum of money that Rigetti can only dream of. Investing in Rigetti Computing is a high-risk endeavor, but if it pays off, shareholders could reap substantial rewards. 2030 is a key milestone in quantum computing To invest in a stock as risky as Rigetti Computing, investors need to be assured that there's an adequate payoff should it win the quantum computing race. Quantum computing has applications in many fields, such as weather forecasting, logistics networks, and artificial intelligence (AI). Numerous other problems can likely be solved by quantum computing which haven't been explored yet. However, it will be a few years before quantum computing becomes widespread. Rigetti Computing estimates that before 2030, the annual value for quantum computing providers will be around $1 billion to $2 billion. However, it expects that opportunity to expand to $15 billion to $30 billion per year between 2030 and 2040. Should Rigetti capture 20% of that market, that's $3 billion in annual revenue. Since the stock is valued at around $4 billion, there's certainly plenty of room for upside. So, should you invest $1,000 in Rigetti Computing? I'd say it depends on your portfolio size. If you have $2,000 to invest, then investing $1,000 into Rigetti Computing is a bad idea. If your portfolio is $100,000 or greater, then this may not be a bad idea if you're a firm believer that Rigetti Computing will win the quantum computing race. There's a ton of risk here, so it may be wiser to spread bets out among multiple quantum computing companies. By keeping your position sizing small, you limit the effect if the stock price reaches zero. But if a 1% position increases 10-fold in value, your portfolio reaps the reward of an incredible investment. Rigetti Computing is a high-risk, high-reward investment, and people need to understand this before investing any money in the stock. Should you invest $1,000 in Rigetti Computing right now? Before you buy stock in Rigetti Computing, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Rigetti Computing wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $652,133!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,056,790!* Now, it's worth noting Stock Advisor's total average return is 1,048% — a market-crushing outperformance compared to 180% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 15, 2025
